04:41 PM EDT, 03/27/2026 (MT Newswires) -- PMGC ( ELAB ) said late Friday its NorthStrive Biosciences unit has entered into a third amendment to its license agreement with MOA Life Plus, a South Korean biotechnology company.

The amendment revises the timing and key development milestones for EL-32 and EL-22 human clinical programs, aligning the schedule with the parties' research, development and regulatory expectations.

EL-32 and EL-22 are experimental drug candidates being developed by NorthStrive, designed to prevent muscle loss in patients undergoing weight-loss treatments.